Cargando…
Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor
The development of pathogenic antibody inhibitors against coagulation factor VIII (FVIII) occurs in ∼30% of patients with congenital hemophilia A receiving FVIII replacement therapy, as well as in all cases of acquired hemophilia A. KM33 is an anti–C1 domain antibody inhibitor previously isolated fr...
Autores principales: | Childers, Kenneth C., Avery, Nathan G., Estrada Alamo, Kevin A., Davulcu, Omar, Haynes, Rose Marie, Lollar, Pete, Doering, Christopher B., Coxon, Carmen H., Spiegel, P. Clint |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352601/ https://www.ncbi.nlm.nih.gov/pubmed/37192299 http://dx.doi.org/10.1182/blood.2023020181 |
Ejemplares similares
-
SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa
por: Childers, Kenneth C., et al.
Publicado: (2022) -
Mechano-covalent protection of coagulation factor VIII by von Willebrand factor
por: Butera, Diego, et al.
Publicado: (2022) -
Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII
por: Vander Kooi, Amber, et al.
Publicado: (2022) -
Cryo-EM structure of coagulation factor V short
por: Mohammed, Bassem M., et al.
Publicado: (2023) -
Factor VIII trafficking to CD4(+) T cells shapes its immunogenicity and requires several types of antigen-presenting cells
por: Kaczmarek, Radoslaw, et al.
Publicado: (2023)